Visión generalGráficoPerfilEstadísticas claveBalance generalTécnicoNoticiasTraderScreen

FORTIS INC/  CA3495531079  /

Toronto
15/11/2024  19:49:05 Diferencia -0.30 Volumen Bid19:49:06 Ask19:49:06 Capitalización de mecado Dividendo A. P/E Ratio
61.97CAD -0.48% 241,767
Volumen de negocios: 14.81 millones		 61.96Volumen de oferta: 1,100 61.98Tamaño/ Volumen/ Formato de Ask: 300 30.43 mil millonesCAD 3.69% 20.01
GlobeNewswire 07/08 Alpha Pro Tech, Ltd. Announces Second Quarter 2024 Financial Results
GlobeNewswire 06/08 FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 31/07 Fortis Inc. Releases Second Quarter 2024 Results and 2024 Sustainability Report
GlobeNewswire 31/07 Fortis Inc. Announces Third Quarter Dividends – 2024
GlobeNewswire 23/07 Advisory: Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire 02/07 Fortis Inc. to Hold Teleconference on July 31 to Discuss Second Quarter 2024 Results
GlobeNewswire 24/06 AstriVax enters clinical phase with its novel vaccine platform technology
GlobeNewswire 18/06 TRIUMPH UNVEILS BONNEVILLE T120 ELVIS PRESLEY LIMITED EDITION
GlobeNewswire 18/06 FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program ...
GlobeNewswire 10/06 Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire 23/05 FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) ...
GlobeNewswire 15/05 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results
GlobeNewswire 08/05 Alpha Pro Tech, Ltd. Announces First Quarter 2024 Financial Results
GlobeNewswire 06/05 FibroGen Reports First Quarter 2024 Financial Results
GlobeNewswire 01/05 Fortis Inc. Releases First Quarter 2024 Results
GlobeNewswire 24/04 Advisory: Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold...
GlobeNewswire 24/04 FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combinat...
GlobeNewswire 23/04 Maryland CareerQuest Connects Area Students with Training and Education Opportunities for Hands-On C...
GlobeNewswire 03/04 Fortis Inc. to Hold Teleconference on May 1 to Discuss First Quarter 2024 Results and Hold Annual an...
GlobeNewswire 02/04 FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metast...
GlobeNewswire 28/03 Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial ...
GlobeNewswire 19/03 AstriVax Rounds Out Executive Team with Chief Business Officer (CBO) Dr. Gregory Fanning
GlobeNewswire 13/03 Alpha Pro Tech, Ltd. Announces Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire 11/03 Fortis Inc. Releases 2024 Climate Report
GlobeNewswire 01/03 Sage Transform 2024 Unveils Sage Copilot and Introduces Groundbreaking Tech Innovations, Product Enh...